TAC (TAC) fluctuates 42.4% within 24 hours: trading volume surges 367% alongside short-term pump
Bitget Pulse2026/03/19 13:13Volatility Brief
Over the past 24 hours, TAC price rebounded from a low of $0.003542 to a high of $0.005044, currently at $0.003921, with a volatility of 42.4%; 24-hour trading volume reached $2.53 million, surging 367.60% compared to the previous day.
Brief Analysis of Abnormal Movement
- Trading volume skyrocketed by 367.60% within 24 hours to $2.53 million, indicating a significant surge in market activity.
- From 07:19 UTC on March 19, the price climbed 18.9% from $0.004063 to $0.004831 within an hour, driving the intraday high.
No official announcement or on-chain whale large transaction report found.
Market Views and Outlook
Market sentiment is slightly optimistic in the short term. CoinGecko data shows the price rose 10.85% in 24 hours, with active trading; X community discussions mention a potential breakthrough above $0.004180, but caution is urged regarding pullback risks. Analysts predict it could reach $0.01050 by the end of 2026.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
